drugset / Trial / NCT00983619
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).
Timeline
- Start
- 2010-04-16
- Primary completion
- 2019-03-21
- Completion
- 2019-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inebilizumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Inebilizumab | Monoclonal antibody | 24 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |